Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension

Persistent liver injury triggers a fibrogenic program that causes pathologic remodelling of the hepatic microenvironment (i.e., liver fibrosis) and portal hypertension. The dynamics of gene regulation during liver disease progression and regression remain understudied. Here, we generated hepatic transcriptome profiles in two well-established liver disease models at peak fibrosis and during spontaneous regression after the removal of the inducing agents. We linked the dynamics of key liver disease readouts, such as portal pressure, collagen proportionate area, and transaminase serum levels, to most differentially expressed genes, enabling the identification of transcriptomic signatures of progressive vs. regressive liver fibrosis and portal hypertension. These candidate biomarkers (e.g., Scube1, Tcf4, Src, Hmga1, Trem2, Mafk, Mmp7) were also validated in RNA-seq datasets of patients with cirrhosis and portal hypertension. Finally, deconvolution analysis identified major cell types and suggested an association of macrophage and portal hepatocyte signatures with portal hypertension and fibrosis area in both models.

[1]  N. Chalasani,et al.  Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease , 2023, Nature Communications.

[2]  J. Bosch,et al.  Increased sinusoidal pressure impairs liver endothelial mechanosensing, uncovering novel biomarkers of portal hypertension , 2023, JHEP reports : innovation in hepatology.

[3]  T. Zacharewski,et al.  Dose-dependent disruption of hepatic zonation by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice: integration of single-nuclei RNA sequencing and spatial transcriptomics , 2022, bioRxiv.

[4]  P. Komolmit,et al.  Non-invasive tests for liver fibrosis assessment in patients with chronic liver diseases: a prospective study , 2022, Scientific Reports.

[5]  F. Tacke,et al.  Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease , 2022, International journal of molecular sciences.

[6]  Eric M Gale,et al.  Peroxidasin Deficiency Re-programs Macrophages Toward Pro-fibrolysis Function and Promotes Collagen Resolution in Liver , 2022, Cellular and molecular gastroenterology and hepatology.

[7]  M. Trauner,et al.  Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies , 2021, Hepatology.

[8]  N. Lanthier,et al.  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. , 2021, The New England journal of medicine.

[9]  G. Hansmann,et al.  PPARγ and TGFβ—Major Regulators of Metabolism, Inflammation, and Fibrosis in the Lungs and Kidneys , 2021, International journal of molecular sciences.

[10]  Wilson Araújo Silva,et al.  CeTF: an R/Bioconductor package for transcription factor co-expression networks using regulatory impact factors (RIF) and partial correlation and information (PCIT) analysis , 2021, BMC Genomics.

[11]  M. Trauner,et al.  Nuclear Receptors in Liver Fibrosis. , 2021, Biochimica et biophysica acta. Molecular basis of disease.

[12]  J. Lozano,et al.  Coexpression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. , 2021, Journal of hepatology.

[13]  Shao-wei Li,et al.  Animal and Organoid Models of Liver Fibrosis , 2021, Frontiers in Physiology.

[14]  D. Gifford,et al.  Ranking Reprogramming Factors for Directed Differentiation , 2021, bioRxiv.

[15]  J. Bosch,et al.  Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. , 2020, Journal of hepatology.

[16]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[17]  Alexander R. Pico,et al.  WikiPathways: connecting communities , 2020, Nucleic Acids Res..

[18]  Neil J Kelly,et al.  SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function , 2020, JACC. Basic to translational science.

[19]  D. Brenner,et al.  Molecular and cellular mechanisms of liver fibrosis and its regression , 2020, Nature Reviews Gastroenterology & Hepatology.

[20]  F. Tacke,et al.  Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities , 2020, Cellular & molecular immunology.

[21]  T. Zacharewski,et al.  Single-Nuclei RNA Sequencing Assessment of the Hepatic Effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin , 2020, Cellular and molecular gastroenterology and hepatology.

[22]  Tamás Korcsmáros,et al.  Integrated intra- and intercellular signaling knowledge for multicellular omics analysis , 2020, bioRxiv.

[23]  B. Schnabl,et al.  Transcriptomic Profiling Identifies Novel Hepatic and Intestinal Genes Following Chronic Plus Binge Ethanol Feeding in Mice , 2020, Digestive Diseases and Sciences.

[24]  Beibei Liu,et al.  CREBH knockout accelerates hepatic fibrosis in mouse models of diet-induced nonalcoholic fatty liver disease. , 2020, Life sciences.

[25]  M. Karsdal,et al.  Collagen biology and non‐invasive biomarkers of liver fibrosis , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[26]  Hong Li,et al.  Insulin‐like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non‐alcoholic fatty liver disease , 2019, Clinical and experimental pharmacology & physiology.

[27]  Gennady Korotkevich,et al.  Fast gene set enrichment analysis , 2019, bioRxiv.

[28]  C. Ponting,et al.  Resolving the fibrotic niche of human liver cirrhosis at single cell level , 2019, Nature.

[29]  M. Trauner,et al.  Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. , 2018, Journal of visualized experiments : JoVE.

[30]  K. Schroder,et al.  Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. , 2018, JCI insight.

[31]  Nancy R. Zhang,et al.  Bulk tissue cell type deconvolution with multi-subject single-cell expression reference , 2018, Nature Communications.

[32]  J. Trebicka,et al.  The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats , 2018, Scientific Reports.

[33]  D. Adams,et al.  Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity , 2018, Nature Reviews Gastroenterology & Hepatology.

[34]  Q. Pan,et al.  Matrix Metalloproteinases (MMPs) in Liver Diseases. , 2017, Journal of clinical and experimental hepatology.

[35]  S. Friedman,et al.  Hepatic stellate cells as key target in liver fibrosis. , 2017, Advanced drug delivery reviews.

[36]  M. McConnell,et al.  Biology of portal hypertension , 2017, Hepatology International.

[37]  Nima S. Hejazi,et al.  biotmle: Targeted Learning for Biomarker Discovery , 2017, J. Open Source Softw..

[38]  A. Osaki,et al.  Increased blood pressure in nesfatin/nuclebindin-2-transgenic mice , 2017, Hypertension Research.

[39]  A. Lohse,et al.  TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice , 2017, Scientific Reports.

[40]  Hai-Jun Li,et al.  Role of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium cantharidinate , 2017, Experimental and therapeutic medicine.

[41]  Yang Zhang,et al.  FOXO transcription factors protect against the diet-induced fatty liver disease , 2017, Scientific Reports.

[42]  Rafael Stern,et al.  Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. , 2016, Journal of hepatology.

[43]  V. Jaks,et al.  The alterations in the extracellular matrix composition guide the repair of damaged liver tissue , 2016, Scientific Reports.

[44]  Hyun-Hee Lee,et al.  MicroRNA Expression Profiling in CCl4-Induced Liver Fibrosis of Mus musculus , 2016, International journal of molecular sciences.

[45]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[46]  Feng Zhang,et al.  Curcumin regulates cell fate and metabolism by inhibiting hedgehog signaling in hepatic stellate cells , 2015, Laboratory Investigation.

[47]  Mercedes Fernandez Molecular pathophysiology of portal hypertension , 2015, Hepatology.

[48]  Isabelle Leclercq,et al.  Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development , 2015, Journal of clinical and translational hepatology.

[49]  M. Strazzabosco,et al.  Emerging roles of Notch signaling in liver disease , 2015, Hepatology.

[50]  Chung-Yen Lin,et al.  cytoHubba: identifying hub objects and sub-networks from complex interactome , 2014, BMC Systems Biology.

[51]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[52]  K. Tomer,et al.  The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease , 2014, PloS one.

[53]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[54]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[55]  P. Carmeliet,et al.  Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice , 2011, Hepatology.

[56]  P. Geurts,et al.  Inferring Regulatory Networks from Expression Data Using Tree-Based Methods , 2010, PloS one.

[57]  Brian P. Dalrymple,et al.  Regulatory impact factors: unraveling the transcriptional regulation of complex traits from expression data , 2010, Bioinform..

[58]  M. Mitterhauser,et al.  Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. , 2009, Journal of hepatology.

[59]  S. Nadler,et al.  MMP7 Shedding of Syndecan-1 Facilitates Re-Epithelialization by Affecting α2β1 Integrin Activation , 2009, PloS one.

[60]  Mark J van der Laan,et al.  Biomarker discovery using targeted maximum‐likelihood estimation: Application to the treatment of antiretroviral‐resistant HIV infection , 2009, Statistics in medicine.

[61]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[62]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[63]  Chung-Yen Lin,et al.  Hubba: hub objects analyzer—a framework of interactome hubs identification for network biology , 2008, Nucleic Acids Res..

[64]  Ana Conesa,et al.  maSigPro: a Method to Identify Significantly Differential Expression Profiles in Time-Course Microarray Experiments , 2006, Spanish Bioinformatics Conference.

[65]  A. Desmoulière,et al.  Fibrillin-1 expression in normal and fibrotic rat liver and in cultured hepatic fibroblastic cells: modulation by mechanical stress and role in cell adhesion , 2004, Laboratory Investigation.

[66]  L. Rasmussen,et al.  Heterogeneity of ductular reactions in adult rat and human liver revealed by novel expression of deleted in malignant brain tumor 1. , 2002, The American journal of pathology.

[67]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[68]  M. Hirai,et al.  Decoding genes with coexpression networks and metabolomics - 'majority report by precogs'. , 2008, Trends in plant science.

[69]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.